| <strong>Managing immunosuppressive therapy at the time of live attenuated vaccination to avoid vaccine‐associated illness</strong> | <strong>Very low</strong>                                     | PICO 23. Should patients with RMD taking drug Y receive live attenuated vaccines?                                     | 952–960                  |